When does Eliquis’ patent expire?
Eliquis (apixaban) patent-life timing depends on which form of intellectual property you mean (drug patents vs. formulation/use patents, and whether you’re looking at the US or another country). The provided information does not include any specific Eliquis patent numbers, jurisdiction, or expiration dates, so the exact expiration date can’t be determined from this prompt alone.
Does the “patent expiration” date mean Eliquis can be marketed right away?
No. Even after relevant patents expire, marketing entry can still be delayed by other patent estates (for different claims) and by regulatory exclusivity in the relevant country. In the US, timing often depends on both patent expiry and FDA exclusivity (and whether a generic/biosimilar applicant successfully challenges listed patents).
How do US generic approvals typically work for Eliquis (apixaban)?
For small-molecule drugs like Eliquis, generic manufacturers typically seek FDA approval based on demonstrating that the proposed product is bioequivalent to the reference listed drug. Whether the generic can be launched on day one of patent expiry depends on which patents are still listed and whether any are held up by litigation or additional controlling claims.
What I need to give you the exact expiration date
If you share any of the following, I can pinpoint the relevant expiration window more precisely:
- Jurisdiction: US, EU/UK, Canada, etc.
- Patent identifiers: the patent number(s) or the Orange Book listing details (or a link)
- Whether you mean: the first patent to expire, the last “blocking” patent, or FDA exclusivity end date
Common quick search terms to find the right date
- “Eliquis Orange Book patents expiration”
- “apixaban patent expiration US”
- “Eliquis FDA Orange Book”
- “apixaban patent list and expiration dates”
Sources: None provided.